
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
GRI Bio is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for diseases linked to immune system dysregulation. The company recently reported positive top-line data from its Phase 2a study of GRI-0621 for the treatment of idiopathic pulmonary fibrosis (IPF). Additionally, GRI Bio's second planned drug product, GRI-0803, is a potential treatment for autoimmune disorders. The company's current valuation is attractive with significant upside potential, and it has a strong pipeline with a Phase 2a trial already underway and promising preclinical work in diseases like lupus and multiple sclerosis.
Bears say
GRI Bio is facing a challenging financial future due to its need to undergo multiple reverse stock splits in the next few years. Additionally, while the company's product candidates show potential for treating serious diseases, the market potential for these diseases (such as lupus and idiopathic pulmonary fibrosis) may not be large enough to generate significant revenue for the company. Furthermore, there is also competition in the market from established biotech companies, which may affect the success rate of GRI Bio's products.
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares